How Glucagon-like Peptide 1 Receptor Agonists Work

Overview

Journal Endocr Connect

Specialty Endocrinology

Date 2021 Jun 17

PMID 34137731

Citations 13

Authors

Christine Rode Andreasen

Andreas Andersen

Filip Krag Knop

Tina Vilsboll

Affiliations

Soon will be listed here.

Abstract

In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over the last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in their ability to improve glycaemia, reduce body weight and in their cardio- and renal protective potentials. Understanding how these agents work, including insights into their pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, their clinical effects and mode of action, and we offer insights into the potential of GLP-1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.

Citing Articles

Hallmarks of Appetite: A Comprehensive Review of Hunger, Appetite, Satiation, and Satiety.

Garutti M, Sirico M, Noto C, Foffano L, Hopkins M, Puglisi F Curr Obes Rep. 2025; 14(1):12.

PMID: 39849268 DOI: 10.1007/s13679-024-00604-w.

GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.

Scheen A Drugs. 2024; 84(11):1347-1364.

PMID: 39342059 DOI: 10.1007/s40265-024-02090-9.

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.

Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C Signal Transduct Target Ther. 2024; 9(1):234.

PMID: 39289339 PMC: 11408715. DOI: 10.1038/s41392-024-01931-z.

Beyond Glycemic Control: GLP-1 Receptor Agonists and Their Impact on Calcium Homeostasis in Real-World Patients.

Alenezi B, Elfezzani N, Uddin R, Patel H, Chester S, Abdelmaksoud A J Clin Med. 2024; 13(16).

PMID: 39201039 PMC: 11355112. DOI: 10.3390/jcm13164896.

Implications of GLP-1 Receptor Agonist on Thyroid Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality and TSH Levels.

Capuccio S, Scilletta S, La Rocca F, Miano N, Di Marco M, Bosco G Biomolecules. 2024; 14(6).

PMID: 38927090 PMC: 11202033. DOI: 10.3390/biom14060687.

References

Thomas M, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K . Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2020; 106(2):388-396. PMC: 7823251. DOI: 10.1210/clinem/dgaa863. View

Gejl M, Gjedde A, Egefjord L, Moller A, Hansen S, Vang K . In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front Aging Neurosci. 2016; 8:108. PMC: 4877513. DOI: 10.3389/fnagi.2016.00108. View

Buse J, Nauck M, Forst T, Sheu W, Shenouda S, Heilmann C . Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2012; 381(9861):117-24. DOI: 10.1016/S0140-6736(12)61267-7. View

Mathieu C, Zinman B, Hemmingsson J, Woo V, Colman P, Christiansen E . Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016; 39(10):1702-10. DOI: 10.2337/dc16-0691. View

Lingvay I, Hansen T, Macura S, Marre M, Nauck M, de la Rosa R . Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Res Care. 2020; 8(2). PMC: 7594204. DOI: 10.1136/bmjdrc-2020-001706. View

Holman R, Bethel M, Mentz R, Thompson V, Lokhnygina Y, Buse J . Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13):1228-1239. PMC: 9792409. DOI: 10.1056/NEJMoa1612917. View

Yamamoto H, Lee C, Marcus J, Williams T, Overton J, Lopez M . Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002; 110(1):43-52. PMC: 151031. DOI: 10.1172/JCI15595. View

Dungan K, Tofe Povedano S, Forst T, Gonzalez J, Atisso C, Sealls W . Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951):1349-57. DOI: 10.1016/S0140-6736(14)60976-4. View

Nicholls S, Bhatt D, Buse J, Del Prato S, Kahn S, Lincoff A . Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2023; 267:1-11. DOI: 10.1016/j.ahj.2023.09.007. View

10.

Baggio L, Yusta B, Mulvihill E, Cao X, Streutker C, Butany J . GLP-1 Receptor Expression Within the Human Heart. Endocrinology. 2018; 159(4):1570-1584. PMC: 5939638. DOI: 10.1210/en.2018-00004. View

11.

Sudo M, Li Y, Hiro T, Takayama T, Mitsumata M, Shiomi M . Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis. 2017; 265:283-291. DOI: 10.1016/j.atherosclerosis.2017.06.920. View

12.

Madsbad S, Dirksen C, Holst J . Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014; 2(2):152-64. DOI: 10.1016/S2213-8587(13)70218-3. View

13.

Athauda D, Gulyani S, Karnati H, Li Y, Tweedie D, Mustapic M . Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. JAMA Neurol. 2019; 76(4):420-429. PMC: 6459135. DOI: 10.1001/jamaneurol.2018.4304. View

14.

Xiao C, Bandsma R, Dash S, Szeto L, Lewis G . Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol. 2012; 32(6):1513-9. DOI: 10.1161/ATVBAHA.112.246207. View

15.

McLean B, Wong C, Campbell J, Hodson D, Trapp S, Drucker D . Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocr Rev. 2020; 42(2):101-132. PMC: 7958144. DOI: 10.1210/endrev/bnaa032. View

16.

Lovshin J, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker D . Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2014; 38(1):132-9. DOI: 10.2337/dc14-1958. View

17.

Ahmann A, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I . Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2017; 41(2):258-266. DOI: 10.2337/dc17-0417. View

18.

Steinberg W, Buse J, Muus Ghorbani M, Orsted D, Nauck M . Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care. 2017; 40(7):966-972. DOI: 10.2337/dc16-2747. View

19.

Johansen N, Dejgaard T, Lund A, Schluntz C, Frandsen C, Forman J . Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020; 8(4):313-324. DOI: 10.1016/S2213-8587(20)30030-9. View

20.

Buse J, Henry R, Han J, Kim D, Fineman M, Baron A . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27(11):2628-35. DOI: 10.2337/diacare.27.11.2628. View